. 2021 Jun 4;13(6):836. doi: 10.3390/pharmaceutics13060836

Table 4.

Forest plots illustrating the overall PPD reduction and CAL gain at 6 months. Refer to Supplementary file 2 for a list of abbreviations.

Overall PPD Reduction for SM Studies at 6 Months
Study	SMD	SE	95% CI	Weight (%)	P = 0.935
Berakdar et al., 2012	0.040	0.296	−0.598 to 0.598	5.08
Malgikar et al., 2015	0.037	0.284	−0.535 to 0.609	5.52
Bundidpun et al., 2017	0.072	0.310	−0.555 to 0.701	4.63
Hill et al., 2019	0.060	0.072	−0.142 to 0.142	84.77
Total (random effects)	0.005	0.066	−0.126 to 0.136	100.00
Heterogeneity: Q = 0.06; DF = 3; P = 0.99; I² = 0.00%
Overall PPD Reduction for PG Studies at 6 Months
Study	SMD	SE	95% CI	Weight (%)	P = 0.809
Arweiler et al., 2014	−0.722	0.342	−1.417 to −0.027	33.04
Vidal et al., 2017	−0.109	0.322	−0.763 to 0.545	33.47
Raut et al., 2018	1.241	0.321	0.594 to 1.888	33.49
Total (random effects)	0.141	0.579	−1.007 to 1.288	100.00
Heterogeneity: Q = 18.71; DF = 2; P = 0.0001; I² = 89.31%
Overall CAL Gain for SM Studies at 6 Months
Study	SMD	SE	95% CI	Weight (%)	P = 0.846
Malgikar et al., 2015	−0.057	0.284	−0.629 to 0.515	5.82
Bundidpun et al., 2017	0.025	0.310	−0.602 to 0.653	4.88
Hill et al., 2019	−0.012	0.072	−0.155 to 0.130	89.30
Total (random effects)	−0.013	0.068	−0.148 to 0.121	100.00
Heterogeneity: Q = 0.03; DF = 2; P = 0.984; I² = 0.00%
Overall CAL Gain for PG Studies at 6 Months
Study	SMD	SE	95% CI	Weight (%)	P = 0.018
Arweiler et al., 2014	−0.539	0.337	−1.224 to 0.146	29.91
Vidal et al., 2017	−0.103	0.322	−0.756 to 0.551	32.69
Raut et al., 2018	−0.658	0.301	−1.265 to −0.050	37.40
Total (random effects)	−0.441	0.184	−0.805 to −0.075	100.00
Heterogeneity: Q = 1.70; DF = 2; P = 0.42; I² = 0.00%